News Release Details

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

May 9, 2024

SAN DIEGO--(BUSINESS WIRE)--May 9, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY

2024 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY

BofA Securities Health Care Conference
Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las Vegas, NV

Live webcasts of each fireside chat will be accessible on the company’s website,, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at and follow us on LinkedIn and Twitter.

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950

Source: Acadia Pharmaceuticals Inc.

Investors Contact

Click here to contact Investor Relations.

Email Alerts

Click here to sign up for email alerts.